Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
29.28
+0.73 (2.56%)
At close: Mar 9, 2026, 4:00 PM EDT
29.28
0.00 (0.00%)
After-hours: Mar 9, 2026, 6:01 PM EDT

Company Description

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.

The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.

It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue.

In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization.

It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors.

The company is headquartered in Alachua, Florida.

Axogen, Inc.
Axogen logo
Country United States
Industry Medical Devices
Sector Healthcare
Employees 622
CEO Michael Dale

Contact Details

Address:
13631 Progress Boulevard, Suite 400
Alachua, Florida 32615
United States
Phone 386 462 6800
Website axogeninc.com

Stock Details

Ticker Symbol AXGN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000805928
CUSIP Number 05463X106
ISIN Number US05463X1063
Employer ID 41-1301878
SIC Code 3845

Key Executives

Name Position
Michael D. Dale President, Chief Executive Officer and Director
Marc A. Began Executive Vice President, General Counsel and Chief Compliance Officer
Jens Schroeder Kemp Chief Marketing Officer
Erick DeVinney Chief Innovation Officer
Lindsey Hartley CPA Chief Financial Officer
Craig A. Swandal Vice President of Operations
Harold D. Tamayo M.B.A. Vice President of Finance and Investor Relations
Doris Quackenbush Vice President of Sales
Dr. Ivica Ducic M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Feb 24, 2026 10-K Annual Report
Feb 24, 2026 8-K Current Report
Jan 23, 2026 8-K Current Report
Jan 23, 2026 424B5 Filing
Jan 21, 2026 424B5 Filing
Jan 21, 2026 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Jan 12, 2026 8-K Current Report
Dec 16, 2025 144 Filing
Dec 16, 2025 144 Filing
Dec 15, 2025 144 Filing